DiagnosticIn Clinical Trials

RGD Peptide Tracers

Intravenous

Overview

RGD peptide tracers are short synthetic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide sequence, which binds to integrin receptors, particularly alphavbeta3, conjugated to positron or gamma-emitting radioisotopes. Alphavbeta3 integrin is upregulated on angiogenic endothelium and many cancer cells, making RGD tracers useful for imaging tumor angiogenesis, metastatic disease, and potentially cardiovascular pathology.

Mechanism of Action

Cyclic RGD peptides and multimeric constructs have been developed to improve binding affinity and tumor retention..

Research Summary & Key Findings

Multiple RGD tracers including 18F-galacto-RGD, 68Ga-NODAGA-RGD, and 18F-fluciclatide have undergone clinical evaluation in cancer imaging trials, with results demonstrating tracer uptake correlating with integrin expression and tumor angiogenesis. Despite promising Phase 1 and Phase 2 data published in the Journal of Nuclear Medicine and Clinical Cancer Research between 2005 and 2016, regulatory approval has not been achieved, in part due to variable tumor uptake and lack of clear clinical decision-making impact.

Clinical Status

In Clinical Trials

RGD Peptide Tracers is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Intravenous

Related Peptides in Diagnostic

Find a Provider

Find a verified provider who offers RGD Peptide Tracers therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply RGD Peptide Tracers.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.